

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUYI INTERNATIONAL PHARMACEUTICAL COMPANY LIMITED

武夷國際藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1889)

**(1) DELAY IN PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENT
FOR THE YEAR ENDED 31 DECEMBER 2016
(2) POSTPONEMENT OF BOARD MEETING
AND
(3) SUSPENSION OF TRADING**

Delay in Publication of Annual Results Announcement for the year ended 31 December 2016

The Board announces that the Company will not be able to publish the Results Announcement in respect of the 2016 Audited Results on or before 31 March 2017 as the Company requires more time and resources to prepare the 2016 Audited Results and resolve the requests from the Auditor, and the Auditor requires more time to complete the audit of 2016 Audited Results.

Postponement of Board Meeting

As a result of the delay in the finalization of the 2016 Audited Results, the Board meeting for the purposes of, among other matters, considering and approving the 2016 Audited Results is therefore postponed to another date to be fixed by the Board.

Suspension of Trading

At the request of the Company, trading in the Company's shares on the Stock Exchange will be suspended with effect from 9:00 a.m. on 3 April 2017 pending the publication of the Results Announcement.

This announcement is made by Wuyi International Pharmaceutical Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.09(2) and 13.49(3) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Delay in Publication of Annual Results Announcement for the year ended 31 December 2016

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces that the Company will not be able to publish the announcement (the “**Results Announcement**”) in respect of the consolidated results of the Group for the year ended 31 December 2016 (the “**2016 Audited Results**”) on or before 31 March 2017 as the Company requires more time and resources to prepare the 2016 Audited Results and resolve the requests from the independent auditor of the Company, Crowe Horwath (HK) CPA Limited (the “**Auditor**”), and the Auditor requires more time to complete the audit of 2016 Audited Results.

The expected date of the publication of the Results Announcement will need to be further agreed with the Auditor and will be announced as and when appropriate.

Pursuant to Rule 13.49(1) of the Listing of Rules, the Company is required to publish the Results Announcement on or before 31 March 2017. The Board acknowledges that the delay in the publication of the Results Announcement will constitute a non-compliance of Rule 13.49(1) of the Listing Rules.

Rule 13.49(3) of the Listing Rules provides that where an issuer is unable to publish its preliminary results in accordance with the requirements of the Listing Rules, it must announce its results based on the financial results which have yet to be agreed with the independent auditor (so far as the information is available). After due and careful consideration, the Board formed the view that as the financial data in relation to the unaudited management accounts of the Group are still being reviewed and finalized by the Company and that the Auditor requires more time to form an opinion on such financial data, it would not be appropriate for the Company to publish the unaudited management accounts of the Group for the year ended 31 December 2016 for the time being as it may be misleading and confusing to shareholders and potential investors.

Postponement of Board Meeting

Reference is made to the announcement of the Company dated 10 March 2017 in relation to the Board meeting to be held on 31 March 2017. As a result of the delay in the finalization of the 2016 Audited Results, the Board meeting for the purposes of, among other matters, considering and approving the 2016 Audited Results is therefore postponed to another date to be fixed by the Board.

Suspension of Trading

At the request of the Company, trading in the Company’s shares on the Stock Exchange will be suspended with effect from 9:00 a.m. on 3 April 2017 pending the publication of the Results Announcement.

By Order of the Board
Wuyi International Pharmaceutical Company Limited
Lin Ou Wen
Chairman and Chief Executive Officer

Hong Kong, 31 March 2017

As at the date of this announcement, the Board comprises 3 Executive Directors, namely, Mr. Lin Ou Wen (Chairman) and Mr. Chen Cheng Qing and Ms. Hung Hoi Lan, and 3 Independent Non-executive Directors, namely, Mr. Zhang Jie, Mr. Zhang Xue Wen and Mr. Wu Cheng Han.